Skip to main content
. 2023 Apr 8;43(5):562–581. doi: 10.1002/cac2.12420

FIGURE 4.

FIGURE 4

M2‐like macrophages accumulation fosters the “immune‐desert” phenotype and impedes the anti‐PD‐1 response in high‐burden tumors, (A) Proportion of M2‐like macrophages in each MC38 subcutaneous tumors group of Figure 3A detected by flow cytometry (n = 3), (B) Proportion of M2‐like macrophages in each B16 subcutaneous tumors group of Figure 3A detected by flow cytometry (n = 3), (C) Schematic diagram of mice treated with PLX3397 (40 mg/kg) and anti‐PD‐1 antibody (10 mg/kg), (D) Subcutaneous tumor and relative tumor volume of each MC38 group on day 27 (n = 3), (E) Before ICI treatment began, proportion of CD3+ CD8+ T cell in MC38 subcutaneous tumors of 4 groups were detected by flow cytometry, (F) Subcutaneous tumor and relative tumor volume of each B16 group on day 27 (n = 3), (G) Before ICI treatment began, proportion of CD3+ CD8+ T cell in B16 subcutaneous tumors of 4 groups were detected by flow cytometry. ns, not significant; *, P < 0.05;, **, P < 0.01; ***, P < 0.001. Abbreviations: HTB, high tumor burden; TME, tumor microenvironment; LTB, low tumor burden; PLX, PLX3397; PD‐1, programmed cell death protein 1.